Musat-Marcu S, Gunter H E, Jugdutt B I, Docherty J C
Institute for Biodiagnostics, National Research Council of Canada, Winnipeg, Canada.
J Mol Cell Cardiol. 1999 May;31(5):1073-82. doi: 10.1006/jmcc.1999.0939.
Macromolecular synthesis inhibitors protect cells from apoptosis in many systems. To determine whether the protein synthesis inhibitor cycloheximide (CHX) might inhibit apoptosis and protect the myocardium during ischemia-reperfusion, we subjected isovolumic isolated perfused rat hearts to 25 min of normothermic global ischemia followed by reperfusion. We monitored coronary flow, end-diastolic pressure and rate-pressure product (RPP) throughout and assessed apoptosis by terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL). Regardless of the treatment regimen (only before ischemia; only during reperfusion; or both before ischemia and during reperfusion), CHX significantly improved functional recovery during reperfusion. These effects were most pronounced when CHX was present during reperfusion. When hearts were treated with CHX only during reperfusion the recovery of sinus rhythm was more frequent in the CHX-treated hearts than control hearts (80% v 53%) and earlier for CHX-treated than control hearts: 6.4 +/- 2 v 19.4 +/- 4.7 min of reperfusion. The maximal RPP recoveries for the CHX-treated hearts were 45 +/- 4.0% (P=0.005) of pre-ischemic values, compared to 26 +/- 3% for controls. In control hearts reperfused for 2 h, TUNEL identified 49.5 +/- 10 intact nuclei and 7.5 +/- 2 fragmented nuclei per 1000 nuclei counted. A significantly lower incidence of labeled nuclei with or without fragmentation was observed in CHX treated hearts: 7.6 +/- 3.4 (P=0.009) intact labeled nuclei and 1.8 +/- 0.7/10(3)fragmented labeled nuclei. Our results suggest that CHX-induced inhibition of apoptosis in reperfused myocardium is cardioprotective and promotes functional recovery in vitro.
在许多系统中,大分子合成抑制剂可保护细胞免于凋亡。为了确定蛋白质合成抑制剂环己酰亚胺(CHX)是否可能在缺血再灌注期间抑制凋亡并保护心肌,我们对离体等容灌注大鼠心脏进行25分钟的常温全心缺血,随后再灌注。我们全程监测冠状动脉流量、舒张末期压力和心率血压乘积(RPP),并通过末端脱氧核苷酸转移酶介导的dUTP缺口末端标记法(TUNEL)评估凋亡情况。无论治疗方案如何(仅在缺血前;仅在再灌注期间;或在缺血前和再灌注期间均使用),CHX均能显著改善再灌注期间的功能恢复。当再灌注期间存在CHX时,这些作用最为明显。当心脏仅在再灌注期间用CHX处理时,CHX处理组心脏窦性心律的恢复比对照组更频繁(80%对53%),且恢复时间早于对照组:再灌注6.4±2分钟对19.4±4.7分钟。CHX处理组心脏的最大RPP恢复为缺血前值的45±4.0%(P=0.005),而对照组为26±3%。在再灌注2小时的对照心脏中,TUNEL检测到每1000个计数的细胞核中有49.5±10个完整细胞核和7.5±2个碎片化细胞核。在CHX处理的心脏中,观察到标记细胞核(无论有无碎片化)的发生率显著降低:7.6±3.4个完整标记细胞核和1.8±0.7/10³个碎片化标记细胞核(P=0.009)。我们的结果表明,CHX诱导的再灌注心肌凋亡抑制具有心脏保护作用,并能促进体外功能恢复。